Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Sarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group Disparities
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
F. Hoffmann-La Roche Ltd: Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
Muscular Dystrophy News1d
Boys with DMD given Elevidys 2 years ago still showing motor gains
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
Sarepta told RBC patient death confirmed unrelated to Elevidys
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
Zawya1d
Qatar: Sidra establishes Gene Therapy Center for rare genetic diseases
The announcement was made at Arab Health 2025 where Sidra Medicine will highlight its international patient service programmes ...
appliedclinicaltrialsonline1d
Elevidys Shows Continued Promise in Phase III EMBARK Trial for the Treatment of Duchenne Muscular Dystrophy
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
precisionmedicineonline2d
Sarepta's DMD Gene Therapy Elevidys Shows Sustained Benefits in Updated Phase III Data
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
PMLiVE2d
Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
biopharma-reporter2d
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Roche reports positive topline outcomes from DMD treatment trial
Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...